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ORIGINAL RESEARCH COMMUNICATION
PAMM: A Redox Regulatory Protein
That Modulates Osteoclast Differentiation
Yan Xu,1,*,{ Leslie R. Morse,2,{ Raquel Assed Bezerra da Silva,3 Paul R. Odgren,4 Hajime Sasaki,1
Philip Stashenko,1 and Ricardo A. Battaglino1
Abstract
The central role of reactive oxygen species (ROS) in osteoclast differentiation and in bone homeostasis prompted
us to characterize the redox regulatory system of osteoclasts. In this report, we describe the expression and
functional characterization of PAMM, a CXXC motif–containing peroxiredoxin 2–like protein expressed in bone
marrow monocytes on stimulation with M-CSF and RANKL. Expression of wild-type (but not C to G mutants of
the CXXC domain) PAMM in HEK293 cells results in an increased GSH=GSSG ratio, indicating a shift toward
a more reduced environment. Expression of PAMM in RAW264.7 monocytes protected cells from hydrogen
peroxide–induced oxidative stress, indicating that PAMM regulates cellular redox status. RANKL stimulation
of RAW 264.7 cells caused a decrease in the GSH=GSSG ratio (reflecting a complementary increase in ROS). In
addition, RANKL-induced osteoclast formation requires phosphorylation and translocation of NF-kB and c-Jun.
In stably transfected RAW 264.7 cells, PAMM overexpression prevented the reduction of GSH=GSSG induced by
RANKL. Concurrently, PAMM expression completely abolished RANKL-induced p100 NF-kB and c-Jun acti-
vation, as well as osteoclast formation. We conclude that PAMM is a redox regulatory protein that modulates
osteoclast differentiation in vitro. PAMM expression may affect bone resorption in vivo and help to maintain bone
mass. Antioxid. Redox Signal. 13, 27–37.
Introduction
Reactive oxygen species (ROS) and other intracellularfree radicals are involved in the control of many cellular
functions, including proliferation, activation, growth inhibi-
tion, regulation of the activity of transcription factors (14, 17),
and apoptosis (16). Yet, at high concentrations, ROS can cause
oxidative stress and induce harmful events like inflammatory
response, apoptosis, or ischemia (13). Cells have developed
several redox systems to protect themselves against cytotoxic
effects of ROS. Oxidative stress, which results in changes in
the redox status of cells, plays important roles in aging as well
as in many diseases, including malignancies, diabetes, neuro-
degenerative diseases, atherosclerosis, ischemia, autoimmu-
nity, and HIV infection (14, 15)
Free radicals also are involved in the pathogenesis of os-
teoporosis (6). Dietary antioxidants (18, 25), levels of plasma
antioxidants (5, 24), and oxidative stress (4) have been all
linked with bone density and the risk of hip fracture. At the
cellular level, ROS have been found to stimulate osteoclastic
bone resorption (22, 23) and osteoclast differentiation (3, 9),
whereas free radical scavengers and antioxidants are inhibi-
tory. ROS, conversely, inhibit osteoblast differentiation (2)
and cause osteocyte apoptosis (20). Bone remodeling is reg-
ulated by the concerted action of osteoblasts (bone formation)
and osteoclasts (bone resorption). Imbalances in the activity or
number of osteoblasts and osteoclasts (or both) can lead to
increases or decreases in bone resorption. This results in
several skeletal diseases, such as osteoporosis, metastatic
bone disease and Paget disease (characterized by increased
bone resorption) or various types of osteopetrosis (charac-
terized by decreased bone resorption).
Redox status affects bone metabolism, including osteo-
clast differentiation (18). Thiol antioxidants are mediators
of estrogen deficiency–induced bone loss. In one study, re-
searchers found decreased levels of glutathione, glutathione
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reductase, thioredoxin-1 (Trx-1), and Trx reductase in bone
marrow (but not liver or spleen) after ovariectomy. Further-
more, this response was rapidly reversed by treatment with
17-b estradiol and was prevented by antioxidants. Finally,
buthionine-(S,R)-sulfoxime (BSO), an inhibitor of glutathione
synthesis, caused bone loss. Bone resorption after estrogen
deficiency might be attributed, in part, to reduced antioxidant
defenses in osteoclasts or other cells or both in the bone
marrow (22). Osteoclast differentiation and function was
shown to be regulated by cellular redox status in a biphasic
way (21), and cellular redox status has been shown to mod-
ulate the nuclear import of transcription factors (1, 18). Fur-
thermore, collectively, these results demonstrate that cellular
redox status affects bone remodeling, at least in part by reg-
ulating osteoclast differentiation.
Two related families of proteins, peroxiredoxins (PRXs) and
thioredoxins (TRXs), are important regulators of cellular re-
dox status in bone and other tissues. PRXs confer a protective
antioxidant role in cells through their peroxidase activity, in
which hydrogen peroxide, peroxynitrate, and organic hydro-
peroxides are reduced and detoxified. TRXs, conversely, alter
the redox state of target proteins by catalyzing the reduction
of their disulfide bonds through a CXXC motif by using redu-
cing equivalents derived from either NADPH or ferredoxins.
In this report, we describe a new member of the pero-
xiredoxin (PRX)-like 2 family, which we have named PAMM
(peroxiredoxin (PRX)-like 2 activated in M-CSF stimulated
monocytes). Members of this family show sequence similarity
to peroxiredoxins. In addition, (PRX)-like 2 proteins, like
PAMM, are similar to thioredoxin in that they contain a CXXC
motif, used by many enzymes with redox regulatory func-
tions. We demonstrate that PAMM is expressed in bone,
brain, liver, and kidney and also is found in bone marrow
monocytes on stimulation with M-CSF and RANKL. We
characterize PAMM expression and activity as well as its
role during osteoclast differentiation. We propose in this re-
port that RANKL-induced osteoclast differentiation requires
PAMM downregulation and a consequent increase in ROS.
Materials and Methods
Microarray hybridization
A genome-wide expression screening was conducted to
identify genes upregulated during RANKL-induced osteo-
clast differentiation, as described previously (7). In brief, total
RNA was extracted from: undifferentiated RAW 264.7
monocytes, osteoclasts derived from RAW 264.7 cells stimu-
lated for 4 days with RANKL, undifferentiated mouse bone
marrow cells (BMMs), and BMMs stimulated with M-
CSFþRANKL for 7 days. The RNA was used as a template to
generate mixed cDNA probes by reverse transcription. These
probes were hybridized to the Mouse MG-U74Av2 chip from
Affymetrix, according to the manufacturer’s instructions, at
the Harvard Bauer Center for Genomics Research (Cam-
bridge, MA).
Reagents
Antibodies against b-actin (no. 4967), NF-kB2 p100=p52
(no. 4882), Phospho-NF-kB2 p100 (Ser866=870) (no. 4810),
Phospho-c-Jun (Ser243) (no. 2994), and Phospho-c-Jun (Ser 63)
(no. 9261) were purchased from Cell Signaling Technology,
Inc. (Danvers, MA). Anti-C10orf58 (PAMM) antibody
(HPA009025) was purchased from Sigma (St. Louis, MO).
G418 was purchased from Invitrogen (Carlsbad, CA).
Cell culture
RAW 264.7 mouse monocytes (TIB-71) were purchased from
ATCC (Manassas, VA). Cells were cultured in DMEM with
1.5 g=L sodium bicarbonate plus 10% non–heat-inactivated
FBS (Invitrogen). DMEM was supplemented with 50 ng=ml
recombinant mouse soluble RANKL (PeproTech, Inc., Rocky
Hill, NJ) for 4 days. Human peripheral blood mononuclear cells
(PBMCs) were isolated from PBS-diluted blood (1:1, vol=vol)
by centrifugation on a Histopaque-1077 (Sigma) density gra-
dient. CD14þ selection was performed by using the Human
CD14 Selection Cocktail (StemCell Technologies, catalog no.
18058). CD14þ PBMCs were cultured for 4 days in a-MEM=
10% FBS supplemented with 180 ng=ml human RANKL
(PeproTech Inc., Rocky Hill, NJ) and 150 ng=ml human M-CSF
(PeproTech Inc.). HEK 293 cells were maintained in DMEM=
10% FBS.
Animals
Animals were obtained from the breeding colony of
toothless (tl) rats maintained at the University of Massachu-
setts Medical School, and all procedures involving animals
were approved by the UMMS IACUC. tl is an autosomal,
dominant, null mutation the Csf-1 gene (31). CSF-1–induced
gene-expression changes in tl=tl rats during the time course of
CSF-1 injections was described in detail in Yang et al. (32). In
brief, animals were injected IP daily with 106 units of recom-
binant human M-CSF (Chiron) for 4 days. One tibia was fixed
in p-formaldehyde and prepared for histologic analysis.
Quantitative RT-PCR and Western blot
Total RNA was extracted from cells and tissues by using
the TRIAZOL reagent (Invitrogen), following the manufac-
turer’s instructions. For RT-PCR, 2mg of RNA was reverse-
transcribed into cDNA by using SuperScript II (Invitrogen,
no. 18064-022) by following the manufacturer’s instructions.
Real-time reverse transcription–polymerase chain reaction
(RT-PCR) was conducted by using the DyNAmo SYBR Green
qPCR Kit (Finnzymes, Espoo, Finland) in a 24-ml reac-
tion volume containing 1ml of a 1:4 dilution of first-strand
reaction product, 1ml of 10mM gene-specific upstream and
downstream primers mixture. Amplification and analysis of
cDNA fragments were carried out by using a 7300 real-time
PCR system (ABI, Foster City, CA). Cycling conditions were
initial denaturation at 958C for 10 min, followed by 40 cycles
consisting of a 15-s denaturation interval at 958C, and a 1-min
annealing and extension interval at 608C. Amplification of
human b-actin mRNA, the housekeeping gene, was used as
an endogenous control to normalize results. Levels of mRNA
expression were measured as threshold levels (Ct) and nor-
malized with the individual b-actin control Ct values. The
primer sequences were as follows: human pamm (C10orf58)
sense, 5’-ATA GAC CTG AAA ACA CTG GA-3’, and anti-
sense, 5’-GCA GCT TCC TCT CGA CAG AG-3’; human
b-actin, sense, 5’-CTC TTC CAG CCT TCC TTC CT-3’, and
antisense, 5’-AGC ACT GTG TTG GCG TAC AG-3’.
Protein lysates were generated by resuspending cells in
Novex Tris-Glycine SDS Sample Buffer (2x) (Invitrogen).
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Equivalent amounts of protein were loaded onto Novex Tris-
Glycine SDS gels (Invitrogen), electrophoresed, and trans-
ferred to nylon membranes by following the manufacturer’s
instructions. After blocking, membranes were incubated with
the indicated primary antibodies overnight at 48C, washed to
remove unbound antibody, and incubated with secondary
antibody for 1 h at room temperature. Chemiluminescent
signal was detected by using the LUMIGLO reagents A and B
(Cell Signaling Technology (Danvers, MA; no. 7003) by fol-
lowing the manufacturer’s instructions. Blots were then ex-
posed to x-ray film.
Immunohistochemistry
Antigen detection on deparaffinized bone sections was
performed according to standard protocols. In brief, sections
were incubated in a humidified chamber overnight at 48C
in primary antibody at the indicated dilutions. The follow-
ing day, the slides were washed 310 min in 1PBSþ 0.1%
(vol=vol) Tween-20. Sections were then incubated for 1 h at
room temperature with the biotinylated secondary antibody
(100 ml=section, diluted 1:250 to 1:750 in blocking buffer) in
a humidified chamber. Finally, slides were washed 310 in
1 PBS and incubated with one drop of ABC (Ready-to-use
Vectastain ABC Kit, Vector Laboratories, Inc., Burlingame,
CA), incubated for 30 min at room temperature, washed
35 min in 1 PBS, and incubated for 2 to 10 min with DAB
solution until signal developed. Images were acquired with a
LEICA DMLS optical microscope equipped with a LEICA DC
100 digital imaging system.
Fluorescent photomicrographs were taken with an
OLYMPUS BX51TRF microscope. Images were captured with
CytoVision version 3.93 Software.
Plasmids, generation of mutants, transfections
An expression plasmid (SC105291) was purchased from
OriGene Technologies (Rockville, MD). This plasmid contains
the entire cDNA for human pamm. Site-directed mutagenesis
was performed by using the Phusion Site-Directed Muta-
genesis Kit (New England Biolabs F-541S) by following the
manufacturer’s instructions. The following primers were used
to generate the 85CXX88C mutants
85C to G:
Sense: (DNA)-Phos-GGT TTC CTC TGT CGA GAG GAA
GCT
Antisense: (DNA)-Phos-GCC TGG CCT CCG CAC GGC
CAT AAT
88C to G:
Sense: (DNA)-Phos-GGT CGA GAG GAA GCT GCG GAT
CTG
Antisense: (DNA)-Phos-GAG GAA ACA GCC TGG CCT
CCG CAC
RAW 264.7 and HEK 293 cells were transfected with the
indicated plasmids by using the Lipofectamine 2000 Trans-
fection Reagent (Invitrogen, no. 11668-019) by following the
manufacturer’s instructions. For the generation of stable
transfectants, we made pIRESneo3=PAMM, in which we in-
serted a NotI-1,000-bp fragment from SC105291 into pIR-
ESneo3 (Clontech Laboratories, Inc., Mountain View, CA).
The NotI insert contains the entire ORF plus 5’ UTR and 3’
UTR. The vector contains the internal ribosome entry site
(IRES) of the encephalomyocarditis virus, which permits the
translation of two open reading frames ( pamm and neomycin
phosphotransferase) from one messenger RNA. Transfected
cells were selected with G418, and nearly all surviving col-
onies stably expressed PAMM. The expression cassette of
pIRESneo3 contains the human CMV major immediate early
promoter.
Measurement of GSH=GSSG ratio
RAW264.7 cells were cultured with RANKL to induce
osteoclast differentiation, harvested at 1-day intervals for 4
days, and stored at708C until use. The GSH=GSSG ratio was
measured with the glutathione reductase=5,5’-dithiobis-
(2-nitrobenzoic acid) (DTNB) assay kit (Bioxytech GSH-412,
OXIS International, Beverly Hills, CA) according to the
manufacturer’s instructions. In brief, total glutathione (GSHt)
and GSSG concentrations were derived from GSH and GSSG
standard curves and converted to nanomoles per milligram
of protein. Reduced GSH concentrations were found by sub-
tracting GSSG from total glutathione. Finally, the GSH=GSSG
ratio was calculated by dividing the difference between total
glutathione and GSSG concentrations by the GSSG concen-
tration [ratio¼GSHt – 2 (GSSG)=GSSG].
Cell-viability assay
Cells were plated at a density of 104 cells=well on 96-well
plates in 100 ml DMEM. Cell viability was evaluated by using
the MTT Based Cell Growth Determination Kit (Sigma-
Aldrich, Cat. no. CGD-1) by following the manufacturer’s
instructions. The amount of MTT formazan produced (which
is proportional to cell number) was determined by measuring
absorbance with a microplate reader (Bio-Rad, Hercules, CA)
at a test wavelength of 570 nm and a reference wavelength of
630 nm.
H2O2 treatment
H2O2 was diluted in PBS and further diluted in culture
medium to the indicated concentrations. Cells were incubated
in H2O2-containing medium for 24 h.
Statistical analysis
Data are presented as means plus or minus 1 SD from
at least three independent experiments. Statistical signifi-
cance was determined by using one-way analysis of vari-
ance (ANOVA) followed by the Student t test (*p< 0.05;
**p< 0.005).
Results
Identification of pamm: sequence, structure,
and orthologues
We previously performed a genome-wide microarray
screening in RAW 264.7 cells as well as in normal BMM
stimulated with RANKL and with M-CSFþRANKL, respec-
tively (7) to identify genes involved in RANKL-induced oste-
oclast formation. Unstimulated cells were used as controls.
We selected only genes whose expression was upregulated
in both cellular model systems of osteoclast differentiation
(RAW 264.7 and BMM). A summary of the results is shown in
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Table 1A. The p value calculated for each gene indicates the
probability of a RANKL-induced increase in gene expression,
with a p value near or equal to zero indicating very high like-
lihood. Some of the top genes identified in this screening are
well-known osteoclast-specific genes—trap, c-fos, cathepsin K,
mmp-9—which validate our screening protocol. We also de-
tected mip-1g, which we found to mediate RANKL-induced
osteoclast formation and survival (27), and NHAoc=NHA2, a
novel gene whose expression is restricted to osteoclasts and is
required for osteoclast terminal differentiation (8, 28).
We identified another gene, which we named pamm [Per-
oxiredoxin (PRX)-like 2 Activated in M-CSF stimulated
monocytes]. pamm mRNA is upregulated in stimulated RAW
264.7 cells and BMM (fold changes relative to unstimulated
cells: 1.41 and 1.48, respectively; Table 1B). pamm is a member
of the peroxiredoxin (PRX)-like 2 family, which is identical to
an uncharacterized human gene: Homo sapiens chromosome
10 open reading frame 58 or C10orf58 (NCBI Reference
Sequence: NM_032333.4). Orthologues of pamm are present
throughout the animal kingdom, including invertebrates (see
http:==www.ncbi.nlm.nih.gov=Structure=cdd=cddsrv.cgi?
uid¼48519 for additional information and sequence align-
ment data). pamm nucleotide-sequence analysis predicts the
existence of a 229-amino acid protein: PAMM (Fig. 1). Mem-
bers of this family of proteins show sequence similarity
to peroxiredoxins (PRXs). In addition, they contain a CXXC
motif, similar to that of thioredoxins (TRXs). The CXXC motif
is used to alter the redox state of target proteins by catalyzing
the reduction of their disulfide bonds. PAMM contains a
putative CXXC motif (C in positions 85 and 88), which sug-
gests that PAMM has redox activity.
PAMM is expressed in M-CSF–activated
macrophages in vitro and in vivo
Western blot analysis of multiple mouse tissues revealed
that PAMM is expressed in kidney, liver, skin, and brain
(Fig. 2A). PAMM also is found in CD14þ human peripheral
blood mononuclear cells (PBMCs) on stimulation with M-CSF
and RANKL (Fig. 2B). Although the upregulation of PAMM
detected in differentiated human PBMCs is modest, it is not
the result of uneven loading, because we could not detect
PAMM expression in unstimulated PBMCs, even when the
blots were exposed for long periods (20 min; data not shown).
Moreover, this level of PAMM upregulation is in agreement
with the expression fold change (1.48) obtained for pamm
RNA (Fig. 1B). To study pamm expression further during
macrophage activation and osteoclast differentiation, we
cultured CD14þ human PBMCs in the presence of M-CSF
alone or M-CSF and RANKL, obtained total RNA from these
cells, and determined pamm relative quantification (RQ) with
quantitative RT-PCR. RQ is commonly used to determine
gene-expression levels in different samples (for instance, un-
differentiated vs. differentiated cells). The target molecule
value is normalized with a reference gene (in our case, b-
actin). Quantitative RT-PCR analysis confirms that although
no pamm mRNA is expressed in unstimulated CD14þ PBMCs,
expression increases (approximately sevenfold) in M-CSF–
Table 1. Summary of Results of Affymetrix Screening
Affymetrix probe seta Gene name p Value (RAW) p Value (BMM)
98859_at Acid phosphatase 5, tartrate-resistant Acp5, trap 0 0
160901_at c-fos 0 0
160406_at Cathepsin K 0 0
99957_at> mmp-9 0 0
104388_at C mip-1g 0 0
96481_at NHAoc=NHA2 0.000001 0
96634_at pamm, C10orf58 0.000004 0.000009
Cell systemb Fold change (unstimulated vs. stimulated)
BMM 1.483
RAW 264.7 1.415
aA partial list displays the top-ranking genes identified in the screening.
bInduction of PAMM in bone marrow monocytes and RAW 264.7 cells.
FIG. 1. Amino acid sequence of
human PAMM. PAMM nucleo-
tide sequence contains an open
reading frame that codes for a
229–amino acid protein. The ami-
no acid sequence predicts a cyto-
plasmic protein. The asterisks
indicate C85 and C88, flanking the
CXXC motif.
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stimulated cells (Fig. 2C). Stimulation with both M-CSF and
RANKL, conversely, resulted in a reduction of pamm mRNA
(Fig. 2C).
Finally, we investigated the expression of PAMM in bone
marrow monocyte activation in vivo, induced by M-CSF in
bone sections from Csf-1-null toothless (tl=tl) rats (32). PAMM
increased significantly in bone marrow cells in tl rats treated
with M-CSF for 4 days (Fig. 2D) compared with that in un-
treated controls. Levels of expression were comparable to
those observed in wild-type rats. These results confirm that
FIG. 2. PAMM expression: mRNA and protein studies. (A) Western blot analysis of mouse proteins shows expression of
PAMM (a band of *25 kDa) in multiple tissues. Kd¼ kidney; Lv¼ liver; Sk¼ skin; Ht¼heart; Br¼ brain; Lg¼ lung. (B)
Western blot analysis of PAMM of protein from human PBMCs shows expression of PAMM under different conditions: ()
unstimulated, and (þ) stimulated with M-CSF plus RANKL. b-Actin was used as a control for loading, Cathepsin k (Cstk) was
used as a control for differentiation in human PBMCs. (C) Relative quantification (RQ) of pamm compared with b-actin, as
determined with quantitative RT-PCR analysis of mRNA from human PBMCs: () unstimulated; M-CSF, stimulated with M-
CSF; M-CSFþRANKL, stimulated with M-CSF plus RANKL for 7 days (the results are expressed as mean SD; n¼ 3). (D)
Histochemical analysis of tibia sections from wild-type (WT) and Toothless (tl=tl) rats by using an anti-PAMM antibody. The
micrographs (magnification, 20) show that PAMM expression in bone marrow monocytes (BMMs) is upregulated by CSF-1
treatment (compare left and center panels). Tb¼ trabecular bone; BM¼ bone marrow. (E) Immunocytochemical analysis of
osteoclasts derived from human CD14þ PBMCs stained with an anti-PAMM antibody and a secondary antibody conjugated
to Alexa Fluor 594. Cells were also stained with DAPI, a nuclear fluorescent dye. The micrographs (magnification, 20) of
unstimulated cells (left) show only DAPI (blue) staining. M-CSF–stimulated cells (center) show DAPI staining and a strong
cytoplasmic PAMM signal (red). PAMM signal decreases in cells stimulated with M-CSF plus RANKL (right panel).
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M-CSF stimulation can activate PAMM expression in BMM
in vivo. Finally, immunocytochemical analysis of human
PBMCs incubated with a specific anti-PAMM antibody (Fig.
2E) confirms that M-CSF alone, as well as M-CSF=RANKL,
can stimulate expression of PAMM, but expression is higher
in M-CSF–stimulated cells.
Overexpression of PAMM inhibits NF-kB
and c-Jun activation and OC differentiation
Our observation that stimulation with RANKL resulted in
decreased PAMM expression in M-CSF–stimulated mono-
cytes (Fig. 2C and E) suggested that downregulation of
PAMM is required for RANKL-induced osteoclast formation.
RANKL-induced osteoclast formation and activation requires
the activation of the transcription factors NF-kB2 and AP-1 (3,
18). NF-kB2 activation, in turn, is augmented by ROS (18). To
study the possible effect of PAMM expression on ROS pro-
duction and osteoclast differentiation, we generated stable
RAW264.7 cell lines constitutively expressing PAMM and
compared the ability of RANKL to induce NF-kB2 and c-Jun
activation, as well as osteoclast differentiation in two inde-
pendent stably-transfected cell lines (PAMM 1 and 2) versus
control (stably transfected with an empty vector) cells. We
found that constitutive expression of PAMM virtually abol-
ished osteoclast formation, as judged by the formation of
osteoclast-like TRAP-positive multinuclear cells (Fig. 3A,
PAMM 1 and PAMM 2). Western blot analysis of protein
extracts from those cells (Fig. 3A, bottom panel) confirmed
that cell lines PAMM 1 and PAMM 2 overexpress PAMM. In a
parallel series of experiments, we incubated RAW264.7 cells
stably transfected with either PAMM or empty vector with
50 ng RANKL for 24 h and prepared protein extracts to ana-
lyze them for activation of NF-kB2 (as shown by cleavage
and phosphorylation of NF100) and c-Jun. We found that,
whereas NF-kB2 and c-Jun were strongly activated in control
RAW264.7 cells (Fig. 3B, lane ), activation was essentially
abolished in PAMM-RAW264.7 cells (Fig. 3B, lanes 1 and 2),
suggesting that PAMM overexpression blocks RANKL in-
duced osteoclast differentiation by inhibiting NF-kB2 and
c-Jun activation.
PAMM expression increases cellular GSH=GSSG ratio
and protects cells from oxidative stress
During osteoclast differentiation, the GSH=GSSG ratio, a
proxy for cellular redox status, decreases in response to M-
CSF and RANKL stimulation. Differentiation of RAW 264.7
monocytes as well as bone marrow monocytes (BMMs) was
associated with a time-dependent decrease in the GSH=GSSG
ratio and a corresponding increase of ROS (18). To examine
whether expression of PAMM could affect the decrease of
GSH=GSSG ratio that follows RANKL stimulation, we stim-
ulated RAW 264.7 PAMM 1 cells with RANKL for 4 days and
determined the GSH=GSSG ratio each day. RAW264.7 cells
transfected with an empty vector were used as controls. We
observed a time-dependent decrease in GSH=GSSG in RAW
264.7 monocytes in response to RANKL stimulation (Fig. 4A,
top), in agreement with previous reports (18). In PAMM-
expressing cells, conversely, the GSH=GSSG ratio increased
with time (Fig. 4A, bottom). This indicates a shift toward
a more-reduced cellular environment in PAMM-expressing
cells, indicating that PAMM has redox regulatory activity. We
also tested this hypothesis in HEK293 cells. For this, we
FIG. 3. PAMM expression blocks RANKL-induced NF-jB2 and c-Jun activation as well as osteoclast differentiation.
Two stably transfected clones of PAMM-expressing RAW 264.7 cells (PAMM 1 and 2) were incubated for 5 days on plastic
coverslips in the presence of RANKL (100 ng=ml). Cells stably transfected with an empty vector were used as controls. (A, top
panel) TRAP staining (red) of control RAW 264.7 cells (-) stimulated for 5 days with RANKL show abundant positive cells as
well as many giant multinucleated osteoclasts (white arrowheads). TRAP-stained cells derived from stimulation of PAMM 1 (1)
and 2 (2) (two independent RAW 264.7 clones stably transfected with a PAMM expression vector) show virtually no positive
cells. (A, bottom panel) Western blot analysis of protein extracts from control RAW264.7, PAMM 1, and PAMM 2 cells by using
an anti-PAMM and b-actin antibody shows that PAMM 1 and PAMM 2 cells overexpress PAMM. (B) Western blot analysis of
protein samples from cells stimulated with RANKL for 24 h indicate phosphorylation=activation of c-Jun (top right panel,
indicated by ) in control cells (). No activation can be seen in either PAMM 1 or 2 cells (1, 2). Similar results can be
observed for NF-kB2 p100=p52 cleavage (center right, indicated by *) and NF-kB2 p100 phosphorylation in Ser866=870)
(bottom right, indicated by ^).
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transiently transfected HEK293 cells with a PAMM expres-
sion plasmid, cultured transfected cells for 24 and 72 h, mea-
sured the GSH=GSSG ratio, and calculated the change in
GSH=GSSG from day 1 to day 3 (Fig. 4B). In control cells
(transfected with an empty vector), the Day3=Day1 ratio was
83%, a decrease that indicates a shift toward a more-oxidized
environment. In PAMM-transfected cells, conversely, the
Day3=Day1 change was 459%, indicating that PAMM ex-
pression shifts the redox status of the cells toward a more-
reduced environment.
We also transfected cells with C85G and C88G mutants, in
which cysteine residues were substituted by glycine at posi-
tions 85 and 88, respectively. These two cysteine residues
form part of the CXXC domain, and presumably are essential
for the ability of PAMM to regulate cellular redox status. The
results (Fig. 4B) show that in cells transfected with either
C85G or C88G mutants, the Day3=Day ratio decreases to
123% and 38%, respectively. These values are similar to those
obtained with the empty vector, confirming that both C
FIG. 4. PAMM expression increases the GSG/GSSG
ratio. (A) Cells (PAMM-expressing RAW 264.7 clone 1, and
RAW 264.7 control) were cultured under differentiation
conditions and collected at 1-day intervals for 4 days after
RANKL-induced OC differentiation. The GSH=GSSG ratio
was measured in these cells’ cytosolic fractions. (Top) GSG=
GSSG ratio decreases in control RAW 264.7 cells as a result
of RANKL-induced osteoclast differentiation (Control)z.
(Bottom) GSG=GSSG ratio, conversely, increases in PAMM-
expressing cells under the same conditions of stimulation, as
a result of the antioxidant activity of PAMM (PAMM 1).
Results are expressed as mean SD (n¼ 3). (B) HEK 293 cells
were transiently transfected with a wild-type PAMM ex-
pression vector (pIRESneo3=PAMM), a mutant version of
PAMM harboring a cysteine 85-to-glycine substitution
(C85G), a mutant version of PAMM with a cysteine 88-
to-glycine substitution (C88G), or co-transfected with C85G
and C88G. Control cells were transfected with an empty
vector (pIRESneo3) or mock-transfected (Mock). Cells were
cultured for 1 and 3 days and harvested. The GSH=GSSG
ratio was measured in these cells’ cytosolic fractions, and
the GSH=GSSGday3 to GSH=GSSGday1 was calculated and
expressed as a percentage. The results indicate that both
cysteines are essential for PAMM antioxidant activity. Co-
transfection of both single mutants does not rescue the ac-
tivity, suggesting that the protein is a functional monomer
(*p< 0.05). (C) Western blot analysis of HEK 293 cells
transfected with the different versions of PAMM [as de-
scribed in (B)] by using an anti-PAMM antibody show
equivalent PAMM expression levels in all transfected cells at
days 1 and 3.
FIG. 5. PAMM expression protects cells from H2O2-
induced oxidative stress. Cell viability decreases in a dose-
dependent manner as a result of oxidative stress induced by
H2O2 treatment of control RAW 264.7 cells (solid black
squares). Viability is increased in PAMM 1 cells (white trian-
gles) as a result of PAMM antioxidant activity. Results are
expressed as mean SD (n¼ 4). (*p< 0.05; **p< 0.005).
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residues (but 88C to a larger extent) are required for PAMM
activity. Finally cotransfection of both mutants (C85G and
C88G) fails to rescue the antioxidant activity, which suggests
that no functional complementation occurs between PAMM
molecules. These values are due to differences in the activity
of PAMM and not to differences in expression levels, because
Western blot analysis (Fig. 4C) shows equivalent expression
levels of PAMM (wild-type and mutant versions) in all
transfected cells.
We next examined the ability of PAMM to protect cells
from oxidative stress. For that, we cultured PAMM-stable
RAW264.7 cells in the presence of H2O2 (ranging from 0 to
1 mM) for 24 h, determined cell viability with the MTT assay,
and expressed it as a percentage of viability with 0 mM H2O2,
as described by Tang et al. (30). RAW 264.7 macrophages were
cultured in parallel under the same conditions. At lower
concentrations (0.05 to 0.1 mM), H2O2 was not cytotoxic. At
higher (0.2 to 1.0 mM) concentrations, however, H2O2 was
cytotoxic in a dose-dependent manner. Compared with con-
trol cells, PAMM-RAW 264.7 cells showed a significantly
greater ability to resist oxidative stress by exogenous hydro-
gen peroxide (Fig. 5). For instance, at 1 mM (a cytotoxic con-
centration of H2O2), only 1.5% of control cells retained
viability, whereas more than 15% of PAMM-expressing cells
were still viable. These results confirm that PAMM expression
can protect cells from oxidative stress induced by H2O2.
The ability of PAMM to inhibit osteoclast formation
depends on cysteines at positions 85 and 88
PAMM expression inhibits osteoclast differentiation in re-
sponse to RANKL by increasing GSH=GSSG, with a corre-
sponding decrease in ROS. In addition, this activity of PAMM
requires cysteine residues 85C and 88C. If PAMM redox ac-
tivity (and no other activity) is responsible for inhibition of
osteoclast differentiation, then cells expressing mutants of
PAMM should be able to undergo RANKL-induced osteoclast
differentiation. To test this hypothesis, we transfected RAW
264.7 cells with C85G and C88G mutants as well as C85G-
C88G double mutants, selected transfected cells in G418-
containing media, and stimulated the transfected cells with
RANKL for 4 days under differentiation conditions. As shown
in Fig. 6A (top panel), both cysteine residues (88C to a larger
extent) are required for the ability of PAMM to inhibit
RANKL-induced osteoclast differentiation, because expres-
sion of mutants C85G and C88G fail to inhibit RANKL-
induced osteoclast formation to the degree that wild-type
PAMM does. These results are in total agreement with
the results shown in Fig. 4. That is, the more a mutation affects
the redox-regulatory activity of PAMM, the more it affects its
ability to inhibit osteoclast formation. Western blot analysis of
protein extracts from transfected cells by using an anti-PAMM
antibody confirms overexpression of PAMM in all transfected
cells (Fig. 6A, bottom panel).
Finally, if PAMM inhibits osteoclast differentiation by re-
ducing ROS cellular levels, the addition of H2O2 should, to a
certain extent, recover the ability of PAMM-expressing cells to
differentiate into osteoclasts. To test this hypothesis, we cul-
tured PAMM-overexpressing cells (1 and 2) in the presence of
RANKL plus a nontoxic concentration (50 mm) of H2O2. The
results (Fig. 6B) clearly show that the addition of H2O2 rescues
the ability of PAMM 1 and PAMM 2 cells to undergo RANKL-
induced differentiation. Both cell lines show increased re-
sponses to the RANKL stimulus, PAMM 2 cells to a greater
degree, as evidenced by formation of numerous multinucle-
ated TRAPþ cells after the addition of H2O2.
Discussion
We report the expression and functional characterization of
a gene that we named pamm: peroxiredoxin (PRX)-like 2 ac-
tivated in M-CSF–stimulated monocytes. This gene is identi-
cal to C10orf58, an uncharacterized gene located on human
chromosome 10q23.1, which is conserved across Bilateria
(http:==www.ncbi.nlm.nih.gov=nucleotide=148596958). pamm
mRNA has a 690-nucleotide open reading frame that codes
for a 229-amino acid protein predicted to have cytoplasmic
localization: PAMM. By immunocytochemical analysis, we
showed that PAMM actually localizes to the cytoplasm.
PAMM expression is enhanced in bone marrow monocytes
stimulated with M-CSF and M-CSF=RANKL compared with
nonstimulated macrophages, and this effect was confirmed in
vivo by injecting M-CSF into M-CSF–negative tl=tl rats. Stable
expression of wild-type PAMM into osteoclast precursor
RAW 264.7 monocytes results in increased levels of reduced
GSH and inhibits RANKL-induced osteoclastic differentia-
tion. Expression of PAMM mutants (C85G, C88G, or C85G to
C88G) in RAW 264.7 monocytes does not prevent cells from
undergoing RANKL-induced osteoclast formation. Expres-
sion of the same mutants in HEK 293 cells shows that both C
residues are required for PAMM redox-regulating activity.
This indicates that precisely this activity of PAMM is re-
sponsible for the inhibition of osteoclast formation. Inhibition
of osteoclast formation by PAMM also was associated with
suppression of NF-kB2 and Jun activation.
Finally, PAMM expression protects cells against oxidative
stress induced by H2O2 treatment. Taken together, these data
shows that PAMM has redox-regulatory activity.
FIG. 6. Mutations in the CXXCmotif and the addition of H2O2 abolish PAMM ability to inhibit osteoclast formation. (A,
top panel) Stably transfected RAW 264.7 clones expressing wild-type (WT) or mutants of PAMM (C85G, C88G, C85G–C88G)
were incubated for 5 days on 48-well plates in the presence of RANKL (50 ng=ml) and then stained for TRAP. Cells stably
transfected with an empty vector (V) and mock-transfected cells () were used as controls. Cells expressing C85G, C88G, and
C85G–C88G mutants generated numerous osteoclasts in response to RANKL, similar to mock-transfected cells or cells
transfected with an empty vector. Cells transfected with a wild-type PAMM, conversely, did not form osteoclasts. (A, bottom
panel) Western blot analysis of protein extracts from: mock-transfected RAW264.7 cells (), wild-type PAMM (WT), C85G
PAMM (85), C88G PAMM (88), C85G–C88G PAMM (85=88), and empty vector (V) by using an anti-PAMM and b-actin
antibody shows that all transfected cells overexpress PAMM (with the exception of mock-transfected cells or cells transfected
with an empty vector). (B) TRAP staining of: control RAW 264.7 cells (V), PAMM 1 and PAMM 2 stimulated with RANKL for
5 days without (, left column) or with 50 mm H2O2 (þ, right column) shows that the addition of H2O2 can reverse the effect of
PAMM expression on osteoclast formation.
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PAMM belongs to the (PRX)-like 2 family of proteins,
which are related to peroxiredoxins by sequence similarity
and also to thioredoxin, because they contain a CXXC motif,
which is used by many enzymes in redox functions. The
second cysteine of the CXXC motif corresponds to the per-
oxidatic cysteine of PRX and is presumed to be essential to
alter the redox status of target proteins. This agrees with our
observation that mutation of C88 (the second cysteine of the
CXXC motif ) has a larger effect in both PAMM redox activity
and the inhibition of osteoclastogenesis. Because PAMM ex-
pression abolishes RANKL-induced NF-kB and Jun activa-
tion, these findings show that PAMM is involved in the
regulation of redox status during osteoclast differentiation,
and they suggest a new mechanism for ROS regulation of
osteoclast activity and function.
PAMM was originally identified as a gene upregulated in
osteoclasts by stimulation with both M-CSF and RANKL. We
found that M-CSF alone was able to induce PAMM expression
in monocytes. The addition of both M-CSF and RANKL re-
sulted in slightly decreased PAMM expression in cell culture.
This observation suggested that PAMM expression could
play a dual role in osteoclastogenesis: inhibiting osteoclast
differentiation while stimulating proliferation of osteoclast
precursors by regulating the levels of intracellular ROS.
RANKL induces the production of ROS that play a central role
in osteoclastogenesis through the RANKL-TRAF6 axis (10). In
addition, osteoclast formation is stimulated by hydrogen
peroxide and inhibited by antioxidants such as N-acetyl cys-
teine (NAC), further demonstrating a role for ROS in osteo-
clast differentiation (22, 23).
Antioxidants regulate bone mass in vivo as well. For in-
stance, although the mechanisms through which estrogen
prevents bone loss are not fully elucidated, it is known that
ovariectomy causes oxidative stress in bone. Consequently,
levels of the main tissue thiol antioxidants, glutathione and
thioredoxin, are substantially reduced in ovariectomized mice
(23). Moreover, ovariectomy also caused a decrease in the
level of the enzymes that regenerate the reduced forms of
glutathione and thioredoxin in the bone marrow. Conversely,
levels of both antioxidants as well as their regenerative
enzymes, were rapidly normalized by a single injection of
17-b estradiol (11, 12). Finally, treatment with antioxidants
prevented estrogen-deficiency bone loss, whereas drugs that
result in reduced thiol antioxidant, like BSO, induced bone
loss. Because we showed that PAMM expression in osteoclast
precursors could inhibit osteoclast formation in vitro, it is
possible that PAMM is a mediator of estrogen-induced inhi-
bition of osteoclastogenesis. This view would establish a
novel mechanistic link between ROS and enhanced bone re-
sorption in which estrogen could protect bone by maintaining
levels of proteins like PAMM. Estrogen deficiency, con-
versely, would result in lower expression of PAMM, leading
to increased osteoclast formation and bone resorption. Fur-
ther experiments aimed at determining the effect of estrogen
on PAMM expression are currently under way.
Alternatively, PAMM expression could be induced by oxi-
dative stress, as with other detoxifying enzymes (26, 29).
Oxidative stress occurs when the normal balance between re-
active oxygen species (ROS) and antioxidants is disrupted as
the result of adverse physiological conditions. This may stem
from a depletion of antioxidants or an excess accumulation of
ROS, which overwhelms the natural coping defenses of the
biologic system. Cells respond to oxidative stress by resetting
critical homeostatic parameters to counteract the oxidant ef-
fects and to restore redox balance. One such cellular response
involves the activation of oxidative stress–activated tran-
scription factors (like NF-kb and Nrf2), leading to the ex-
pression of genes encoding antioxidant enzymes, like PAMM.
In this view, PAMM expression would increase in bone
marrow cells from ovariectomized animals, because oxidative
stress that results from estrogen deficiency would trigger that
homeostatic response. Further experiments, aimed at study-
ing changes in the expression of PAMM as well as in the
activation of NF-kb and Nrf2 in ovariectomized mice, also are
under way.
In conclusion, we report the identification, expression, and
functional analysis of a gene, pamm, which codes for a novel
PRX-like 2 protein with redox regulatory activity. Expression
of PAMM is increased in CD14þ monocytes stimulated with
M-CSF and decreases as M-CSF–stimulated cells undergo
RANKL-dependent osteoclast differentiation. We have
shown that overexpression of PAMM in RAW 264.7 cells is
associated with inhibited NF-kB2 and AP-1 activation and
impaired osteoclastogenesis in response to RANKL. We also
have shown that cysteine residues at position 85 and espe-
cially cysteine at position 88 are required for those activities.
Studies addressing the transcriptional control of PAMM ex-
pression by Nrf-2 and the expression of PAMM in bone in vivo
after ovariectomy are currently under way. Understanding
this novel mechanism will aid in the design of novel therapies
to reduce oxidative stress by modulating PAMM expression
or activity and potentially to prevent osteoporosis and other
forms of bone loss.
Acknowledgments
We thank Ms Justine Dobeck for technical assistance and
Subbiah Yoganathan for expertise with animal experimen-
tation. The work was supported by grant K12 HD001097-08
to LRM from NIH=NICHD, and grant RO1 DE07444 to PRO
from the US NIDCR. Opinions expressed are those of the
authors and do not necessarily represent those of the US
NIH.
Author Disclosure Statement
The authors have nothing to disclose.
References
1. Aitken CJ, Hodge JM, Nishinaka Y, Vaughan T, Yodoi J, Day
CJ, Morrison NA, and Nicholson GC. Regulation of human
osteoclast differentiation by thioredoxin binding protein-2
and redox-sensitive signaling. J Bone Miner Res 19: 2057–
2064, 2004.
2. Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA,
Roberson PK, Kousteni S, O’Brien CA, Bellido T, Parfitt AM,
Weinstein RS, Jilka RL, and Manolagas SC. Skeletal involu-
tion by age-associated oxidative stress and its acceleration
by loss of sex steroids. J Biol Chem 282: 27285–27297, 2007.
3. Asagiri M and Takayanagi H. The molecular understanding
of osteoclast differentiation. Bone 40: 251–264, 2007.
4. Banfi G, Iorio EL, and Corsi MM. Minireview: oxidative
stress, free radicals and bone remodeling. Clin Chem Lab Med
46: 1550–1555, 2008.
36 XU ET AL.
5. Banfi G, Malavazos A, Iorio E, Dolci A, Doneda L, Verna R,
and Corsi MM. Plasma oxidative stress biomarkers, nitric
oxide and heat shock protein 70 in trained elite soccer
players. Eur J Appl Physiol 96: 483–486, 2006.
6. Basu S, Michaelsson K, Olofsson H, Johansson S, and Melhus
H. Association between oxidative stress and bone mineral
density. Biochem Biophys Res Commun 288: 275–279, 2001.
7. Battaglino R, Fu J, Spate U, Ersoy U, Joe M, Sedaghat L, and
Stashenko P. Serotonin regulates osteoclast differentiation
through its transporter. J Bone Miner Res 19: 1420–1431, 2004.
8. Battaglino RA, Pham L, Morse LR, Vokes M, Sharma A,
Odgren PR, Yang M, Sasaki H, and Stashenko P. NHA-oc=
NHA2: a mitochondrial cation-proton antiporter selectively
expressed in osteoclasts. Bone 42: 180–192, 2008.
9. Boyce BF, Yamashita T, Yao Z, Zhang Q, Li F, and Xing L.
Roles for NF-kappaB and c-Fos in osteoclasts. J Bone Miner
Metab 23(suppl): 11–15, 2005.
10. Boyle WJ, Simonet WS, and Lacey DL. Osteoclast differen-
tiation and activation. Nature 423: 337–342, 2003.
11. Chow JW. Ovariectomy and estrogen replacement in ro-
dents. Methods Mol Med 80: 361–365, 2003.
12. Chow JW, Tobias JH, Colston KW, and Chambers TJ. Es-
trogen maintains trabecular bone volume in rats not only by
suppression of bone resorption but also by stimulation of
bone formation. J Clin Invest 89: 74–78, 1992.
13. Davies KJ. Oxidative stress: the paradox of aerobic life.
Biochem Soc Symp 61: 1–31, 1995.
14. Droge W. Free radicals in the physiological control of cell
function. Physiol Rev 82: 47–95, 2002.
15. Franco R, Schoneveld OJ, Pappa A, and Panayiotidis MI.
The central role of glutathione in the pathophysiology of
human diseases. Arch Physiol Biochem 113: 234–258, 2007.
16. Haddad JJ. Antioxidant and prooxidant mechanisms in the
regulation of redox(y)-sensitive transcription factors. Cell
Signal 14: 879–897, 2002.
17. Holmgren A. Antioxidant function of thioredoxin and glu-
taredoxin systems. Antioxid Redox Signal 2: 811–820, 2000.
18. Huh YJ, Kim JM, Kim H, Song H, So H, Lee SY, Kwon SB,
Kim HJ, Kim HH, Lee SH, Choi Y, Chung SC, Jeong DW,
and Min BM. Regulation of osteoclast differentiation by the
redox-dependent modulation of nuclear import of tran-
scription factors. Cell Death Differ 13: 1138–1146, 2006.
19. Kaptoge S, Welch A, McTaggart A, Mulligan A, Dalzell N,
Day NE, Bingham S, Khaw KT, and Reeve J. Effects of
dietary nutrients and food groups on bone loss from the
proximal femur in men and women in the 7th and 8th de-
cades of age. Osteoporos Int 14: 418–428, 2003.
20. Kikuyama A, Fukuda K, Mori S, Okada M, Yamaguchi H,
and Hamanishi C. Hydrogen peroxide induces apoptosis of
osteocytes: involvement of calcium ion and caspase activity.
Calcif Tissue Int 71: 243–248, 2002.
21. Kim H, Kim IY, Lee SY, and Jeong D. Bimodal actions of re-
active oxygen species in the differentiation and bone-resorbing
functions of osteoclasts. FEBS Lett 580: 5661–5665, 2006.
22. Lean JM, Davies JT, Fuller K, Jagger CJ, Kirstein B, Par-
tington GA, Urry ZL, and Chambers TJ. A crucial role for
thiol antioxidants in estrogen-deficiency bone loss. J Clin
Invest 112: 915–923, 2003.
23. Lean JM, Jagger CJ, Kirstein B, Fuller K, and Chambers TJ.
Hydrogen peroxide is essential for estrogen-deficiency bone
loss and osteoclast formation.Endocrinology 146: 728–735, 2005.
24. Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani
M, Mecocci P, Senin U, Pacifici R, and Cherubini A. Marked
decrease in plasma antioxidants in aged osteoporotic wom-
en: results of a cross-sectional study. J Clin Endocrinol Metab
88: 1523–1527, 2003.
25. Morton DJ, Barrett-Connor EL, and Schneider DL. Vitamin
C supplement use and bone mineral density in postmeno-
pausal women. J Bone Miner Res 16: 135–140, 2001.
26. Niture SK, Kaspar JW, Shen J, and Jaiswal AK. Nrf2 sig-
naling and cell survival. Toxicol Appl Pharmacol 2009 June 16
[Epub ahead of print].
27. Okamatsu Y, Kim D, Battaglino R, Sasaki H, Spate U, and
Stashenko P. MIP-1 gamma promotes receptor-activator-
of-NF-kappa-B-ligand-induced osteoclast formation and
survival 1. J Immunol 173: 2084–2090, 2004.
28. Pham L, Purcell P, Morse L, Stashenko P, and Battaglino RA.
Expression analysis of nha-oc=NHA2: a novel gene selectively
expressed in osteoclasts. Gene Expr Patterns 7: 846–851, 2007.
29. Scandalios JG. Oxidative stress: molecular perception and
transduction of signals triggering antioxidant gene defenses.
Braz J Med Biol Res 38: 995–1014, 2005.
30. Tang D, Shi Y, Kang R, Li T, Xiao W, Wang H, and Xiao X.
Hydrogen peroxide stimulates macrophages and monocytes
to actively release HMGB1. J Leukoc Biol 81: 741–747, 2007.
31. Van WL, Odgren PR, MacKay CA, D’Angelo M, Safadi FF,
Popoff SN, Van HW, and Marks SC Jr. The osteopetrotic
mutation toothless (tl) is a loss-of-function frameshift mu-
tation in the rat Csf1 gene: evidence of a crucial role for CSF-
1 in osteoclastogenesis and endochondral ossification. Proc
Natl Acad Sci U S A 99: 14303–14308, 2002.
32. Yang M, Mailhot G, MacKay CA, Mason-Savas A, Aubin J,
and Odgren PR. Chemokine and chemokine receptor ex-
pression during colony stimulating factor-1-induced osteo-
clast differentiation in the toothless osteopetrotic rat: a key
role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo
and in vitro. Blood 107: 2262–2270, 2006.
Address correspondence to:
Ricardo A. Battaglino, Ph.D.
140 The Fenway
Boston, MA 02115
E-mail: rbattaglino@forsyth.org
Date of first submission to ARS Central, September 9, 2009;
date of final revised submission, November 23, 2009; date of
acceptance, December 1, 2009.
Abbreviations Used
BM¼ bone marrow
BMM¼ bone marrow monocyte
BSO¼ buthionine sulfoximine
C10orf58¼ chromosome 10 open reading frame 58
CSF-1¼ colony-stimulating factor 1
GSH¼ reduced glutathione
GSSG¼ oxidized glutathione
M-CSF¼macrophage colony-stimulating factor
PAMM¼peroxiredoxin activated in M-CSF–activated
monocytes
PBMC¼peripheral blood mononuclear cell
RANKL¼ receptor activator for nuclear factor-kB
ligand
ROS¼ reactive oxygen species
Tb¼ trabecular bone
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